In early September CreagerCole worked closely with our client Callen-Lorde Community Health Center in New York City to help coordinate placment of an op-ed by Nala Toussaint. Toussaint is Callen-Lorde’s Prevention Coordinator for Transgender Services.
The commentary, featured at TheBody.com, explores how a national injectable estrogen shortage brings added health risks for trans women living with HIV.
“For trans women who are HIV positive, a lack of access to proper hormone treatment can compound their health problems. It can make them more vulnerable to becoming indifferent about their overall self-care.”
“I join my fellow health care providers in imploring Par Sterile and Perrigo Pharmaceuticals to take all necessary steps to replenish injectable estrogen immediately. While these manufacturers wait, the health and well-being of trans women (particularly those with HIV or at risk for HIV) hang in the balance. We must do better by our trans communities. The time is now,” she argued.